Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Receivables: 2021-2025

Historic Change in Receivables for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to $19.8 million.

  • Kiniksa Pharmaceuticals International's Change in Receivables rose 346.97% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 22.92%. This contributed to the annual value of $20.5 million for FY2024, which is 137.72% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Change in Receivables stood at $19.8 million, which was up 343.19% from -$8.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Change in Receivables high stood at $25.5 million for Q1 2022, and its period low was -$21.6 million during Q2 2022.
  • Moreover, its 3-year median value for Change in Receivables was $4.4 million (2024), whereas its average is $3.6 million.
  • Data for Kiniksa Pharmaceuticals International's Change in Receivables shows a peak YoY increase of 1,114.19% (in 2023) and a maximum YoY decrease of 744.85% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Change in Receivables stood at $686,000 in 2021, then surged by 118.80% to $1.5 million in 2022, then soared by 1,114.19% to $18.2 million in 2023, then dropped by 7.62% to $16.8 million in 2024, then soared by 346.97% to $19.8 million in 2025.
  • Its Change in Receivables stands at $19.8 million for Q3 2025, versus -$8.2 million for Q2 2025 and -$1.7 million for Q1 2025.